Furthermore, the identification of distinct variations in p16 expression across different tumor locations emphasizes the need for personalized approaches to HNSCC management tailored to the specific biological characteristics of each patient's tumor. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.